Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 2/20 | 0.71 |
| ▸ | ATM | Q13315 | 1/20 | 0.69 |
| ▸ | POLB | P06746 | 1/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.68 |
| ▸ | MEN1 | O00255 | 2/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.67 |
| ▸ | USP2 | O75604 | 1/20 | 0.67 |
| ▸ | TSHR | P16473 | 1/20 | 0.65 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.64 |
| ▸ | HTT | P42858 | 1/20 | 0.63 |
| ▸ | LMNA | P02545 | 1/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.61 |
| ▸ | HPGD | P15428 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1711115 | 0.90 | PKM (0.85) | PKMPOLBKMT2AMEN1USP2 | |
| SCHEMBL5472315 | 0.89 | PKM (0.72) | PKMATMPOLBKMT2AMEN1 | |
| SCHEMBL8200020 | 0.83 | KMT2A (0.84) | PKMATMPOLBKMT2AMEN1 | |
| SCHEMBL9386579 | 0.83 | KMT2A (0.84) | PKMATMPOLBKMT2AMEN1 | |
| SCHEMBL7564728 | 0.83 | KMT2A (0.84) | PKMATMPOLBKMT2AMEN1 | |
| SCHEMBL423283 | 0.82 | MAPT (0.74) | PKMPOLBKMT2AMEN1USP2 | |
| SCHEMBL3236916 | 0.82 | MAPT (0.80) | PKMPOLBKMT2AMEN1SMN1; SMN2 | |
| SCHEMBL7106543 | 0.81 | ATM (0.69) | ATMPOLBKMT2AMEN1SMN1; SMN2 | |
| SCHEMBL1156725 | 0.81 | ATM (0.69) | ATMPOLBKMT2AMEN1SMN1; SMN2 | |
| SCHEMBL160108 | 0.81 | ATM (0.69) | PKMATMPOLBKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3246034-A1 | BORON-CONTAINING SMALL MOLECULES AS ANTI-INFLAMMATORY AGENTS | Anacor Pharmaceuticals, Inc. (US) | 2017-11-22 | — | — | EP | disclosed |
| US-20160318955-A1 | Boron-Containing Small Molecules as Anti-Inflammatory Agents | ANACOR PHARMACEUTICALS, INC. | 2016-11-03 | — | — | US | disclosed |
| US-20160318955-A1 | Boron-Containing Small Molecules as Anti-Inflammatory Agents | ANACOR PHARMACEUTICALS, INC. | 2016-11-03 | — | — | US | disclosed |
| US-9416146-B2 | Boron-containing small molecules as anti-inflammatory agents | ANACOR PHARMACEUTICALS, INC. (US) | 2016-08-16 | — | — | US | disclosed |
| US-9416146-B2 | Boron-containing small molecules as anti-inflammatory agents | ANACOR PHARMACEUTICALS, INC. (US) | 2016-08-16 | — | — | US | disclosed |
| US-9212147-B2 | Dihydroxy aromatic heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-12-15 | — | — | US | disclosed |
| US-9212147-B2 | Dihydroxy aromatic heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-12-15 | — | — | US | disclosed |
| US-20150291629-A1 | Boron-Containing Small Molecules as Anti-Inflammatory Agents | ANACOR PHARMACEUTICALS, LLC | 2015-10-15 | — | — | US | disclosed |
| US-20150291629-A1 | Boron-Containing Small Molecules as Anti-Inflammatory Agents | ANACOR PHARMACEUTICALS, LLC | 2015-10-15 | — | — | US | disclosed |
| US-9012431-B2 | Boron-containing small molecules as anti-inflammatory agents | ANACOR PHARMACEUTICALS, INC. (US) | 2015-04-21 | — | — | US | disclosed |
| US-20110003787-A1 | NOVEL PHENYLPYRROLE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-01-06 | — | — | US | disclosed |
| EP-2239253-A1 | NOVEL PHENYLPYRROLE DERIVATIVE | Daiichi Sankyo Company, Limited (JP) | 2010-10-13 | — | — | EP | disclosed |
| US-20090291917-A1 | Boron-Containing Small Molecules as Anti-Inflammatory Agents | ANACOR PHARMACEUTICALS, INC. (US) | 2009-11-26 | — | — | US | disclosed |
| US-20090291917-A1 | Boron-Containing Small Molecules as Anti-Inflammatory Agents | ANACOR PHARMACEUTICALS, INC. (US) | 2009-11-26 | — | — | US | disclosed |
| WO-2009111676-A2 | BORON-CONTAINING SMALL MOLECULES AS ANTI-INFLAMMATORY AGENTS | ANACOR PHARMACEUTICALS, INC (US) | 2009-09-11 | — | — | WO | disclosed |
| US-6743787-B2 | FOR THERAPY OF METABOLIC DISORDERS MEDIATED BY INSULIN RESISTANCE OR HYPERGLYCEMIA IN A MAMMAL | WYETH | 2004-06-01 | — | — | US | disclosed |
| US-20030027795-A1 | N-(4-sulfonylaryl)cyclylamine-2-hydroxyethylamines as beta-3 adrenergic receptor agonists | WYETH | 2003-02-06 | — | — | US | disclosed |
| US-6444685-B1 | THERAPY FOR METABOLISM DISEASES; DIETETICS; ANTIDIABETIC AGENTS | WYETH | 2002-09-03 | — | — | US | disclosed |
| US-20020028797-A1 | N-(4-sulfonylaryl)Cyclylamine 2-hydroxyethylamines as beta-3 adrenergic receptor agonists | AMERICAN HOME PRODUCTS CORPORATION | 2002-03-07 | — | — | US | disclosed |
| WO-2002006274-A1 | N-(4-SULFONYLARYL)CYCLYLAMINE-2-HYDROXYETHYLAMINES AS BETA-3 ADRENERGIC RECEPTOR AGONISTS | WYETH (US) | 2002-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110003787-A1 | NOVEL PHENYLPYRROLE DERIVATIVE | GCKR, GCK, SLC5A1 | PKM 156/4885ATM 2738/4885POLB 4619/4885 |
| US-20090291917-A1 | Boron-Containing Small Molecules as Anti-Inflammatory Agents | NFKBIA, LITAF, CD68 | PKM 4744/4885ATM 3670/4885POLB 1963/4885 |
| US-20160318955-A1 | Boron-Containing Small Molecules as Anti-Inflammatory Agents | NFKBIA, LITAF, CD68 | PKM 4744/4885ATM 3670/4885POLB 1963/4885 |
| US-20030027795-A1 | N-(4-sulfonylaryl)cyclylamine-2-hydroxyethylamines as beta-3 adrenergic receptor agonists | ADRB3, ADRB1, ADRB2 | PKM 1871/4885ATM 4030/4885POLB 3400/4885 |
| US-20150291629-A1 | Boron-Containing Small Molecules as Anti-Inflammatory Agents | NFKBIA, LITAF, CD68 | PKM 4744/4885ATM 3670/4885POLB 1963/4885 |
| US-20020028797-A1 | N-(4-sulfonylaryl)Cyclylamine 2-hydroxyethylamines as beta-3 adrenergic receptor agonists | ADRB3, ADRB1, ADRB2 | PKM 1385/4885ATM 4109/4885POLB 3228/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.